Got new Email. Here it is:
> Dr. Erich Mohr Appointed Chairman of TrichoScience
>
> February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
> (TrichoScience) has announced the appointment of Dr. Erich Mohr
> (PhD, R.Psych) as the Company's new Chairman of the Board of
> Directors, effective immediately. Dr. Mohr also serves as
> Chairman and CEO of MedGenesis Therapeutix Inc., a company he
> founded in 2006.
>
> Dr. Mohr, who was a Professor of Medicine and Psychology at the
> University of Ottawa until 1997, has over 25 years of experience
> in experimental therapeutics of CNS disorders. He is credited
> with over 150 publications, books, book chapters and abstracts
> and has edited the, Handbook of Clinical Trials: The
> neurobehavioral approach. Dr. Mohr has chaired and/or served
> on several regulatory advisory panels for the approval of new
> products for the treatment of neurodegenerative disease. He is
> the former Chairman and Chief Executive Officer of CroMedica
> Global Inc., which was merged with PRA International in 2002,
> and co-founder of several biotechnology companies. Prior to his
> founding of MedGenesis, he served as Chief Scientific Officer
> for PRA International. PRA is one of the top five contract
> research organizations in the world. Over the course of his
> career, Dr. Mohr has overseen and/or participated in dozens of
> clinical development programs resulting in a number of approved
> drugs.
>
> In announcing the appointment, former TrichoScience Chairman,
> Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
> Chairmanship of TrichoScience marks an important milestone in
> the development of our Company. He brings a depth of invaluable
> experience that will help shape and guide the Company as it
> heads into one of its most important periods of growth and
> maturity. His knowledge of and direct participation in both
> clinical trials and the regulatory approvals' process brings a
> level of hands-on experience and a base of knowledge that will
> be of significant benefit to the Company at this time."
>
> Concurrent with Dr. Mohr's appointment, Dr. McLean has been
> named Chairman of TrichoScience's new Corporate Advisory Board.
>
>
>
>
> About TrichoScience
> TrichoScience Innovations Inc. (TrichoScience) is a
> privately-held life sciences company based in Vancouver,
> Canada. The company is developing a new hair cell replication
> technique that has the potential to become the world's first
> non-surgical, permanent cure for pattern baldness and general
> hair loss in both men and women. The procedure, a non-surgical,
> cellular implantation method that replicates a patient's hair
> cells from their own healthy hair follicles, is being developed
> by a team of recognized research scientists and medical experts
> in the fields of hair growth, hair biology and dermatology.
> Patents covering the procedure have been issued in a number of
> international jurisdictions and are patent-pending in other
> major countries worldwide.
>
> The TrichoScience procedure is not yet commercially available
> and is subject to human clinical trials followed by regulatory
> submission, review and approvals in Canada, Europe and the
> United States.
>
> Please visit our website at http://www.trichoscience.com
>
>
> Disclaimer
> Except for historical information, this news or information
> release may contain statements that reflect the Company's
> current expectations regarding future events. Such statements
> are subject to a number of risks and uncertainties, including
> changing market conditions, successful and timely completion of
> clinical studies, establishment of corporate alliances, the
> impact of competitive products and pricing, issues related to
> the regulatory approval process and other risks that may be
> detailed in the Company's ongoing reporting.
What you think?!
> Dr. Erich Mohr Appointed Chairman of TrichoScience
>
> February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
> (TrichoScience) has announced the appointment of Dr. Erich Mohr
> (PhD, R.Psych) as the Company's new Chairman of the Board of
> Directors, effective immediately. Dr. Mohr also serves as
> Chairman and CEO of MedGenesis Therapeutix Inc., a company he
> founded in 2006.
>
> Dr. Mohr, who was a Professor of Medicine and Psychology at the
> University of Ottawa until 1997, has over 25 years of experience
> in experimental therapeutics of CNS disorders. He is credited
> with over 150 publications, books, book chapters and abstracts
> and has edited the, Handbook of Clinical Trials: The
> neurobehavioral approach. Dr. Mohr has chaired and/or served
> on several regulatory advisory panels for the approval of new
> products for the treatment of neurodegenerative disease. He is
> the former Chairman and Chief Executive Officer of CroMedica
> Global Inc., which was merged with PRA International in 2002,
> and co-founder of several biotechnology companies. Prior to his
> founding of MedGenesis, he served as Chief Scientific Officer
> for PRA International. PRA is one of the top five contract
> research organizations in the world. Over the course of his
> career, Dr. Mohr has overseen and/or participated in dozens of
> clinical development programs resulting in a number of approved
> drugs.
>
> In announcing the appointment, former TrichoScience Chairman,
> Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
> Chairmanship of TrichoScience marks an important milestone in
> the development of our Company. He brings a depth of invaluable
> experience that will help shape and guide the Company as it
> heads into one of its most important periods of growth and
> maturity. His knowledge of and direct participation in both
> clinical trials and the regulatory approvals' process brings a
> level of hands-on experience and a base of knowledge that will
> be of significant benefit to the Company at this time."
>
> Concurrent with Dr. Mohr's appointment, Dr. McLean has been
> named Chairman of TrichoScience's new Corporate Advisory Board.
>
>
>
>
> About TrichoScience
> TrichoScience Innovations Inc. (TrichoScience) is a
> privately-held life sciences company based in Vancouver,
> Canada. The company is developing a new hair cell replication
> technique that has the potential to become the world's first
> non-surgical, permanent cure for pattern baldness and general
> hair loss in both men and women. The procedure, a non-surgical,
> cellular implantation method that replicates a patient's hair
> cells from their own healthy hair follicles, is being developed
> by a team of recognized research scientists and medical experts
> in the fields of hair growth, hair biology and dermatology.
> Patents covering the procedure have been issued in a number of
> international jurisdictions and are patent-pending in other
> major countries worldwide.
>
> The TrichoScience procedure is not yet commercially available
> and is subject to human clinical trials followed by regulatory
> submission, review and approvals in Canada, Europe and the
> United States.
>
> Please visit our website at http://www.trichoscience.com
>
>
> Disclaimer
> Except for historical information, this news or information
> release may contain statements that reflect the Company's
> current expectations regarding future events. Such statements
> are subject to a number of risks and uncertainties, including
> changing market conditions, successful and timely completion of
> clinical studies, establishment of corporate alliances, the
> impact of competitive products and pricing, issues related to
> the regulatory approval process and other risks that may be
> detailed in the Company's ongoing reporting.
What you think?!
